Macular Degeneration Clinical Trial
Official title:
Evaluation of the Retinal Health Monitoring System - Retinal Thickness Module in Subjects With Normal Macular Thickness and Subjects With Center-involving Macular Edema
NCT number | NCT04428242 |
Other study ID # | SCT-202 |
Secondary ID | |
Status | Withdrawn |
Phase | |
First received | |
Last updated | |
Start date | April 2020 |
Est. completion date | July 2020 |
Verified date | February 2021 |
Source | Kubota Vision Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 2020 |
Est. primary completion date | June 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Corrected visual acuity (VA) of 20/100 or better, in the study eye(s) 2. Media clarity, undilated pupil size, OCT-B scans, axial length measurements in the study eye(s) 3. Able to perform self-testing of retinal thickness with the RHMS-RTM after training 4. Able and willing to give informed consent 5. Group 1: 1. Macula with normal thickness [central subfield thickness (CST) below 305 microns as measured by SD-OCT] in at least one eye 2. Patients with dry AMD are eligible for enrollment into Group 1 3. No history of wet AMD, DR, or RVO in either eye 6. Group 2 and Group 3 (in at least one or the same eye): 1. History of center-involving macular edema due to wet AMD (Group 2); or DR or RVO (Group 3) 2. Macular edema on SD-OCT with CST = 305 microns Exclusion Criteria: 1. History of corneal refractive surgery, photorefractive keratectomy, radial keratotomy, in the study eye 2. History of epiretinal membrane, vitreomacular traction, or macular hole in the study eye(s) 3. Participation in any study using an investigational drug within 30 days or screening or investigational device within 60 days of screening 4. Refractive error: spherical equivalent of > 3 diopters of hyperopia or > 6 diopters of myopia, or > 2 diopters cylinder in the study eye(s) 5. History of photocoagulation laser scar or other retinal scar in the central 3 mm of the macula, in the study eye(s) |
Country | Name | City | State |
---|---|---|---|
United States | Retinal Consultants Medical Group, Inc | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
Kubota Vision Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of the RHMS-RTM retinal thickness measurements | To evaluate the ability of the RHMS-RTM device to measure retinal thickness | 1 day | |
Primary | RHMS-RTM repeatability | To assess repeatability of the RHMS-RTM device | 1 day | |
Primary | Comparison of retinal thickness measurements between the RHMS-RTM and the SD-OCT | To evaluate the agreement of measurements by the RHMS-RTM and SD-OCT | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Completed |
NCT02540954 -
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
|
Phase 3 | |
Completed |
NCT00385333 -
Metabolic Mapping to Measure Retinal Metabolism
|
Phase 2 | |
Completed |
NCT02510794 -
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
Terminated |
NCT02228304 -
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Completed |
NCT02181504 -
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01204541 -
A Single-Center Pilot Study to Assess Macular Function
|
N/A | |
Completed |
NCT00769392 -
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
|
N/A | |
Completed |
NCT00533520 -
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
|
Phase 4 | |
Withdrawn |
NCT00538538 -
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
|
Phase 1 | |
Completed |
NCT00536016 -
A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
|
Phase 1 | |
Terminated |
NCT00403442 -
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
|
Phase 1 | |
Recruiting |
NCT00157976 -
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
|
Phase 3 | |
Completed |
NCT00239928 -
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00211458 -
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
|
Phase 2 | |
Completed |
NCT00242580 -
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
|
Phase 3 | |
Completed |
NCT00095433 -
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
|
Phase 3 | |
Completed |
NCT00006202 -
Lutein for Age-Related Macular Degeneration
|
Phase 2 |